

**MTN 030 - Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings**  
**Report Generation Date: December 2, 2025**  
**Visit Cutoff Date: February 15, 2018<sup>1</sup>**  
**Retention by Visit and Site**

	<b>All Sites</b>	<b>Birmingham, AL</b>	<b>Pittsburgh, PA</b>
Participants Enrolled	24	12	12
<b>Day 1</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	24 (100%)	12 (100%)	12 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
<b>Day 2</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	24 (100%)	12 (100%)	12 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
<b>Day 3</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	24 (100%)	12 (100%)	12 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 030 - Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings**  
**Report Generation Date: December 2, 2025**  
**Visit Cutoff Date: February 15, 2018<sup>1</sup>**  
**Retention by Visit and Site**

	<b>All Sites</b>	<b>Birmingham, AL</b>	<b>Pittsburgh, PA</b>
<b>Day 7</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	24 (100%)	12 (100%)	12 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
<b>Day 14 PUEV/Early termination Visit</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	24 (100%)	12 (100%)	12 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0
<b>Day 15</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	23 (96%)	12 (100%)	11 (92%)
Not Completed	1 (4%)	0 (0%)	1 (8%)
Missed	1 (4%)	0 (0%)	1 (8%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 030 - Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings**  
**Report Generation Date: December 2, 2025**  
**Visit Cutoff Date: February 15, 2018<sup>1</sup>**  
**Retention by Visit and Site**

	<b>All Sites</b>	<b>Birmingham, AL</b>	<b>Pittsburgh, PA</b>
<b>Day 16</b>			
Expected <sup>2</sup>	24	12	12
Completed <sup>3</sup>	24 (100%)	12 (100%)	12 (100%)
Not Completed	0 (0%)	0 (0%)	0 (0%)
Missed	0 (0%)	0 (0%)	0 (0%)
Terminated Early	0 (0%)	0 (0%)	0 (0%)
Not Expected	0	0	0

<sup>1</sup> This report includes data received and entered at SCHARP through this date.

<sup>2</sup> A visit is considered expected only once the participant's visit window has closed.

<sup>3</sup> A visit is considered completed once the Visit Summary form is received and entered at SCHARP.